Enhancement of percutaneous absorption of Finasteride by cosolvents, cosurfactant and surfactants

Pharmaceutical Development and Technology

Volumn 15, Issue 6, 2010, Pages 619-625

  Javadzadeh, Yousef ^a   Shokri, Javad ^a   Hallaj Nezhadi, Somayeh ^b   Hamishehkar, Hamed ^a   Nokhodchi, Ali ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Androgenic alopecia treatments; Enhanced skin permeability; Finasteride; Percutaneous absorption enhancer

Indexed keywords

ANIONIC SURFACTANT; CATIONIC SURFACTANT; DIETHYLENE GLYCOL MONOETHYL ETHER; FINASTERIDE; PROPYLENE GLYCOL;

ANIMAL TISSUE; ARTICLE; DRUG ABSORPTION; DRUG FORMULATION; DRUG PENETRATION; IN VITRO STUDY; MALE; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN ABSORPTION;

5-ALPHA REDUCTASE INHIBITORS; ADMINISTRATION, CUTANEOUS; ANIMALS; ETHYLENE GLYCOLS; EXCIPIENTS; FINASTERIDE; MALE; RATS; RATS, WISTAR; SKIN ABSORPTION; SOLVENTS; SURFACE-ACTIVE AGENTS;

EID: 78149231666     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903397610     Document Type: Article

References (40)

1. Price VH. Treatment of hair loss. N Eng J Med 1999;341:964-973.
2. Hamilton JB. Patterned loss of hair in man; types and incidence. Ann NY Acad Sci 1951;53:708-728.
3. Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses 2004;62:112-115.
4. Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, Fiedler V, Lucky A, Whiting DA, Pappas F, Culbertson J, Kotey P, Meehan A, Waldstreicher J. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000:43:768-776.
5. Sinclair R.D. Male androgenetic alopecia J. Mens. Health Gend. 2004 1 319-327
6. Sinclair RD. Male androgenetic alopecia (Part II). J Mens Health Gend 2005;2:38-44.
7. Sovak M, Seligson AL, Kucerova R, Bienova M, Hajduch M, Bucek M. Fluridil, a rationally designed topical agent for androgenetic alopecia: First clinical experience. Dermatol Surg 2002;28:678-685.
8. Van Neste D, Fuh V, Sanchez-Pedreno P, Lopez-Bran E, Wolff H, Whiting D, Roberts J, Kopera D, Stene JJ, Calvieri S, Tosti A, Prens E, Guarrera M, Kanojia P, He W, Kaufman KD. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 2000;143:804-810.
9. Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, Kraus S, Baldwin H, Shalita A, Draelos Z, Markou M, Thiboutot D, Rapaport M, Kang S, Kelly T, Pariser D, Webster G, Hordinsky M, Rietschel R, Katz HI, Terranella L, Best S, Round E, Waldstreicher J. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999;40:930-937.
10. Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol 2002;46:517-523.
11. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998;39: 578-589.
12. Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol 2002;12:32-37.
13. Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S.Enhancement of follicular delivery of finasteride by liposomes and niosomes 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm 2006;323:1-10.
14. Kumar R, Singh B, Bakshi G, Katare OP. Development of liposomal systems of Finasteride for topical applications: Design, characterization, and in vitro evaluation. Pharm Dev Technol 2007;12:591-601.
15. Gabrijelcic V, Sentjurc M. Influence of hydrogels on liposome stability and on the transport of liposome entrapped substances into the skin. Int J Pharm 1995;118:207-212.
16. Auner BG, Petzenhauser E, Valenta C. Influence of 6-ketocholestanol on skin permeation of 5-aminolevulinic acid and evaluation of chemical stability. J Pharm Sci 2004;93:2780-2787.
17. El Maghraby G.M.M. Williams A.C. Barry B.W. Interactions of surfactants edge activators and skin penetration enhancers with liposomes Int. J. Pharm.1 2004 276 143-161
18. El Maghraby GMM, Williams AC, Barry BW. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm 2004;276:143-161.
19. Barry B.W. Dermatological formulations percutaneous absorption New York: Marcel Dekker 1983 127-233
20. Lopez A, Llinares F, Cortell C, Herraez M. Comparative enhancer effects of span 20 with Tween 20 and Azone on the in vitro percutaneous penetration of compounds with different lipophilicities. Int J Pharm 2000;202:133-140.
21. Santoyo S, Ygartua P. Effect of skin pretreatment with fatty acidson percutaneous absorption and skin retention of piroxicam after its topical application. Eur J Pharm Biopharm 2000;50:245-250.
22. Williams AC, Barry BW. Essential oils as novel human skin penetration enhancers. Int J Pharm 1989;57:7-9.
23. Scheuplein RJ, Blank IH. Permeability of the skin. Physiol Rev 1971;51:702-747.
24. Curdy C, Kalia YN, Naik A, Guy RH. Piroxicam delivery into human stratum corneum in vivo: Iontophoresis versus passive diffusion. J Control Release 2001;11:73-79.
25. Mura P, Faucci MT, Bramanti G, Corti P. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci 2000;9: 365-372.
26. Panchagnula R. Salve P.S. Thomas N.S. Jain A.K. Ramarao P. Transdermal delivery of naloxone: Effect of water propylene glycol ethanol and their binary combinations on permeation through rat skin Int. J. Pharm. 2001;219:95-105.
27. Panchagnula R. Salve P.S. Thomas N.S. Jain A.K. Ramarao P. Transdermal delivery of naloxone: Effect of water propylene glycol ethanol and their binary combinations on permeation through rat skin. Int J Pharm 2001;219:95-105.
28. Nokhodchi A, Shokri J, Dashbolaghi A, Hassan-Zadeh D, Ghafourian T, Barzegar-Jalali M. The enhancement effect of surfactants on the penetration of lorazepam through rat skin. Int J Pharm 2003;250:359-369.
29. Shokri J, Nokhodchi A, Dashbolaghi A, Hassan-Zadeh D, Ghafourian T, Barzegar Jalali M. The effect of surfactants on the skin penetration of diazepam. Int J Pharm 2001;228:99-107.
30. Riegelman S. Crowell W. The kinetics of rectal absorption II the absorption of anions J. Am. Pharm. Assoc. Am. Pharm. Assoc. Baltim 1958; 47 123-127.
31. Riegelman S, Crowell W. The kinetics of rectal absorption. II. The absorption of anions. J Am Pharm Assoc Am Pharm Assoc (Baltim) 1958;47:123-127.
32. Riegelman S. Crowell W.J. The kinetics of rectal absorption. I. Preliminary investigations into the absorption rate process. J Am Pharm Assoc Am Pharm Assoc (Baltim) 1958;47:115-122.
33. Riegelman S Crowell WJ. The kinetics of rectal absorption. III. The absorption of undissociated molecules. J Am Pharm Assoc Am Pharm Assoc (Baltim) 1958; 47: 127-133.
34. Aguiar AJ, Weiner MA. Percutaneous absorption studies of chloramphenicol solutions. J Pharm Sci 1969;58: 210-215.
35. Ribaud C, Garson JC, Doucet J, Leveque JL. Organization of stratum corneum lipids in relation to permeability: Influence of sodium lauryl sulfate and preheating. Pharm Res 1994;11:1414-1418.
36. Froebe CL, Simion FA, Rhein LD, Cagan RH, Kligman A. Stratum corneum lipid removal by surfactants: Relation to in vivo irritation. Dermatologica 1990;181:277-283.
37. Leveque JL, de Rigal J, Saint-Leger D, Billy D. How does sodium lauryl sulfate alter the skin barrier function in man? A multiparametric approach. Skin Pharmacol 1993;6:111-115.
38. Blank IH, Gould E, Theobald A. Penetration of cationicsurfactants into skin. J Invest Dermatol 1964;42: 363-366.
39. Borras-Blasco J, Lopez A, Morant MJ, Diez-Sales O, Herraez-Domingues M. Influence of sodium lauryl sulphate on the in vitro percutaneous absorption of compounds with different lipophilicity. Eur J Pharm Sci 1997;5:15-22.
40. Cooper ER. Increased skin permeability for lipophilic molecules. J Pharm Sci 1984;73:1153-1156.